Education
About Us
Working with TipRanks
Follow Us
Ezekowitz Alan Insider Profile
4 Followers
Ezekowitz Alan, Director at Fulcrum Therapeutics, holds ― shares in Fulcrum Therapeutics (Ticker: FULC), holds ― shares in Organon (Ticker: OGN), holds 117.42K shares in Septerna, Inc. (Ticker: SEPN). Most recently, Ezekowitz Alan ― shares of Fulcrum Therapeutics on ― for an estimated value of ―.
Ezekowitz Alan has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Ezekowitz Alan holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Ezekowitz Alan
Ezekowitz Alan's Trading History
Fulcrum Therapeutics
―
Director
―
―
Organon
―
Director
―
―
Septerna, Inc.
Mar 10, 2025
Director
Informative Buy
92.17K
$755.01K
List of latest transactions for each holding click on a transaction to see Ezekowitz Alan's performance on stock
You May Also Like
Ezekowitz Alan insider profile FAQ
What is the percentage of profitable transactions made by Ezekowitz Alan?
The percentage of profitable transactions made by Ezekowitz Alan is ―.
What is the average return per transaction made by Ezekowitz Alan?
The average return per transaction made by Ezekowitz Alan is ―.
What stocks does Ezekowitz Alan hold?
Ezekowitz Alan holds: FULC, OGN, SEPN stocks.
What was Ezekowitz Alan’s latest transaction?
Ezekowitz Alan latest transaction was an Uninformative Buy of ―.
What was Ezekowitz Alan's most profitable transaction?
Ezekowitz Alan’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Ezekowitz Alan's role in Fulcrum Therapeutics?
Ezekowitz Alan's role in Fulcrum Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.